# Johnson & Johnson (JNJ) — News

JNJ · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/jnj/news

## Recent headlines

- [J&J: Raymond James cuts target price to $278 from $280](https://www.ainvest.com/news/raymond-james-cuts-target-price-278-280-2610) — AInvest Wire, Oct 14, 2026
  Raymond James has adjusted its price target for Johnson & Johnson (JNJ), reducing it to $278 from the previous $280, according to recent analyst activity . The move reflects ongoing evaluations of the company’s performance amid mixed results across its business segments. While the pharmaceutical…
- [J&J: Leerink Partners cuts target price to $272 from $276](https://www.ainvest.com/news/leerink-partners-cuts-target-price-272-276-2610) — AInvest Wire, Oct 14, 2026
  Leerink Partners has revised its target price for Johnson & Johnson (J&J) from $276 to $272, reflecting a modest downward adjustment in its valuation outlook for the company [1]. The change, while relatively small, signals a recalibration of expectations amid ongoing market analysis and performance…
- [J&J: BofA global research cuts price objective to $275 from $282](https://www.ainvest.com/news/bofa-global-research-cuts-price-objective-275-282-2610) — AInvest Wire, Oct 14, 2026
- [Johnson & Johnson shares down 3.9% after Q3 results](https://www.ainvest.com/news/johnson-johnson-shares-3-9-q3-results-2610) — AInvest Wire, Oct 13, 2026
  Johnson & Johnson (JNJ) shares fell 3.9% following the release of its third-quarter earnings results, underperforming broader market indices. The stock closed at $239.63, marking a significant decline from the previous day’s close. The S&P 500 lost 0.57%, while the Dow Jones Industrial Average…
- [J&J exec says we remain on track for the planned separation of DePuy Synthes by mid 2027 - Conf. call](https://www.ainvest.com/news/exec-remain-track-planned-separation-depuy-synthes-mid-2027-conf-call-2610) — AInvest Wire, Oct 13, 2026

## Similar Stocks

- [PFE](https://www.lighthorse.io/tickers/pfe) — Pfizer, Inc. Common Stock
- [ABBV](https://www.lighthorse.io/tickers/abbv) — AbbVie Inc. Common Stock
- [MRNA](https://www.lighthorse.io/tickers/mrna) — Moderna, Inc. - Common Stock
- [AZN](https://www.lighthorse.io/tickers/azn) — AstraZeneca PLC Ordinary Shares
- [MRK](https://www.lighthorse.io/tickers/mrk) — Merck & Company, Inc. Common Stock (new)
- [LLY](https://www.lighthorse.io/tickers/lly) — Eli Lilly and Company Common Stock
- [PG](https://www.lighthorse.io/tickers/pg) — Procter & Gamble Company (The) Common Stock
- [XOM](https://www.lighthorse.io/tickers/xom) — ExxonMobil Holdings Corporation Common Stock
- [NVAX](https://www.lighthorse.io/tickers/nvax) — Novavax, Inc. - Common Stock
- [BRK.B](https://www.lighthorse.io/tickers/brk.b) — Berkshire Hathaway Inc. New Common Stock

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).